Joseph Tintelnot

Joseph Tintelnot is a Clinical Professor and Senior Physician specializing in Internal Medicine, Hematology, and Oncology at the University of Hamburg's Faculty of Medicine. He is affiliated with the II. Medical Clinic and Polyclinic and the Center for Oncology at the University Medical Center Hamburg-Eppendorf (UKE). His research focuses on immuno-oncology, targeted cancer therapies, and the role of microbiota in cancer treatment efficacy. He leads clinical trials investigating novel therapeutic combinations for HER2-positive esophagogastric cancers, pancreatic cancer, and autoimmune hepatitis. Key contributions include studies on ctDNA biomarkers, immune checkpoint inhibitor efficacy, and microbiome interactions with chemotherapy.

Research interests span immunotherapy resistance mechanisms, liquid biopsy applications, and translational oncology. He collaborates on multi-institutional trials (e.g., RAMONA, INTEGA) analyzing treatment response predictors and adverse event profiles. His work emphasizes personalized medicine approaches, integrating genomic and clinical data for improved patient outcomes.